Whitepapers
The Cellution to Autoimmunity? The promise and perils of CAR-T
Whitepaper
Dec 6, 2024
Navigating Real World Evidence Requirements
Whitepaper
Dec 2, 2024
NICE’s Proportional Approach to Technology Appraisals
Whitepaper
Oct 31, 2024
Long Follow-Up in Short Supply
Whitepaper
Aug 5, 2024
Potential Impact of the IRA on the Generic Drug Market
Will the Inflation Reduction Act transform the generic drug market and disrupt cost savings? Our white paper explores the potential impact of the IRA on generics. Learn how CMS drug price negotiations, revenue shifts, and market access challenges could reshape the landscape.
Whitepaper
Jul 2, 2024
Patient Journey Empowerment: Realizing the potential for patients and your brand
Whitepaper
Dec 11, 2023
Competitive Planning and Response: Where to focus for sustained success
Whitepaper
Nov 22, 2023
Penetrating the CNS – Strategic Implications of an Increasingly Flexible FDA
Whitepaper
Nov 21, 2023
Cracking the Code: Unlocking Key Opinion Leaders in the Digital Landscape
Whitepaper
Nov 14, 2023
Half-time in the EU HTA Regulation Roll Out
Whitepaper
Sep 22, 2023
Before You Start the Strategic Planning Cycle: 5 essential things to streamline your approach
Whitepaper
Sep 11, 2023
ICER Value Assessment Framework Update 2023
How will the proposed updates to the ICER Value Assessment
Framework affect manufacturers preparing to launch products in the US? In this whitepaper, we present an overview of ICER’s work to date, highlighting key trends and providing insights into the impact of the coincidental timing between the ICER Value Assessment Framework update and new IRA process.
Whitepaper
Aug 31, 2023